WHWK

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2010, for Zeta Acquisition Corp. II (the "Company"). The Company is a Delaware corporation organized as a "blank check" company and a "shell company" with the sole purpose of seeking a business combination, merger, or acquisition with an unidentified target. As of the reporting date, the Company had not identified any target business, conducted no active operations, and generated no revenue. The filing notes a discrepancy in the request metadata regarding the company name; the document explicitly identifies the registrant as Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc.

Key Financial Metrics

Note: The Company has no debt other than notes payable to stockholders. Margins are not applicable due to zero revenue.

Material Changes vs. Prior Period

• Liabilities Increased: Total liabilities rose from $31,613 in 2009 to $70,389 in 2010, primarily driven by an increase in notes payable to stockholders from $25,000 to $60,000.
• Cash Position Improved: Cash and cash equivalents increased by $15,756 (141%) year-over-year, funded entirely by financing activities (stockholder loans).
• Accumulated Deficit: The accumulated deficit during the development stage grew to $(90,991) from inception through 2010, compared to $(68,596) at the end of 2009.
• Operating Expenses: General and administrative expenses increased slightly to $20,509 in 2010 from $19,158 in 2009, consisting of professional fees and interest.

Outlook, Risks, and Management Commentary

Going Concern: Management explicitly states that the Company's ability to continue as a going concern is dependent on its ability to generate future profitable operations and/or obtain necessary financing. There are no assurances that additional funding will be available.

Business Plan: The Company intends to seek a business combination with an operating company. It has no specific business plan or target identified. Management anticipates incurring costs related to filing reports and investigating potential acquisitions over the next 12 months.

Risks:

• Liquidity Risk: The Company has no funds in its treasury aside from cash on hand and is dependent on related parties for continued funding.
• Competition: The Company faces intense competition from other "public shell" and "blank check" companies for potential acquisition targets.
• Dilution: In a potential tax-free reorganization, existing stockholders may retain 20% or less of the surviving entity, resulting in substantial dilution.
• Management Resources: Officers and directors are engaged in outside business activities and devote limited time to the Company.

Unusual Items: The Company utilizes office space and equipment of its management at no cost. No compensation was paid to officers or directors during the period.

Investor Verification Checklist

• Identity Verification: Confirm the registrant is Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc., as the metadata suggested.
• Capital Adequacy: Verify the Company's ability to meet obligations given the negative working capital (Current Assets $29,398 vs. Current Liabilities $70,389).
• Related Party Dependence: Assess the risk associated with $60,000 in notes payable to stockholders and the reliance on these parties for future funding.
• Shell Status: Confirm the Company remains a "shell company" with no operations, meaning investment value is entirely speculative based on a future merger.
• Stockholder Dilution: Review the potential for significant dilution if a reverse merger or business combination is consummated.